60 Degrees Pharmaceuticals, Inc. Common Stock (SXTP) is a publicly traded Healthcare sector company. As of May 21, 2026, SXTP trades at $1.38 with a market cap of $3.80M and a P/E ratio of -0.12. SXTP moved -1.42% today. Year to date, SXTP is -28.86%; over the trailing twelve months it is -85.23%. Its 52-week range spans $1.29 to $49.80. Analyst consensus is buy with an average price target of $14.10. Rallies surfaces SXTP's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
60 Degrees Pharma Launches Weekly ARAKODA Malaria Prevention on Runway Health: 60 Degrees Pharmaceuticals has launched ARAKODA® (tafenoquine) for once-weekly malaria prevention on Runway Health’s telehealth platform, allowing U.S. travelers to obtain prescriptions and home delivery before departure. ARAKODA, FDA-approved in 2018 for adults, features a 16-day half-life and broad-spectrum dosing after an initial three-day loading phase.
| Metric | Value |
|---|---|
| Price | $1.38 |
| Market Cap | $3.80M |
| P/E Ratio | -0.12 |
| EPS | $-11.73 |
| Dividend Yield | 0.00% |
| 52-Week High | $49.80 |
| 52-Week Low | $1.29 |
| Volume | 1.47K |
| Avg Volume | 0 |
| Revenue (TTM) | $1.01M |
| Net Income | $-7.37M |
| Gross Margin | 22.26% |
2 analysts cover SXTP: 0 strong buy, 2 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $14.10.